PRIOR AUTHORIZATION CRITERIA

BRAND NAME (generic)

SYMPROIC (naldemedine)

Status: CVS Caremark® Criteria Type: Initial Prior Authorization

POLICY

FDA-APPROVED INDICATIONS

Symproic is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation.

COVERAGE CRITERIA

The requested drug will be covered with prior authorization when the following criteria are met:

• The requested drug is being prescribed for the treatment of opioid-induced constipation (OIC) in an adult patient with chronic non-cancer pain, including chronic pain related to prior cancer or its treatment who does not require frequent (e.g., weekly) opioid dosage escalation

Duration of Approval (DOA):

1713-A: DOA: 12 months

REFERENCES

- 1. Symproic [package insert]. Raleigh, NC: BioDelivery Sciences International, Inc.; July 2021.
- Lexicomp Online, AHFS DI (Adult and Pediatric) Online. Waltham, MA: UpToDate, Inc.; 2023. https://online.lexi.com. Accessed July 25, 2023.
- 3. Micromedex (electronic version). Merative, Ann Arbor, Michigan, USA. Available at: https://www.micromedexsolutions.com/ (cited: 07/25/2023).

Symproic PA Policy UDR 10-2023.docx

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark.